Following disappointing data for lirentelimab in atopic dermatitis and chronic spontaneous urticaria, the US biotech has discontinued development of the anti-siglec 8 antibody, laid off half of its employees and placed its future hopes on the Phase I compound AK006.

Latest data show a worrying public health trend that remains the top health concern in China despite surging COVID infections.

A landmark approval and domestic tie-up in China mark the fast innovation that is shaping the country’s health sector.

Private Company Edition: The astonishing pace of venture capital investment in drug development continues with another $1.5bn in financings of $100m or more, including $152m for Pyxis and $126m for Omega. New VC funds also continue to launch, including RiverVest’s fifth fund, totaling $275m.